openPR Logo
Press release

Diabetic Neuropathic Pain - Pipeline Insight, 2025: Innovation in Non-Opioid Therapies and Disease-Modifying Approaches Gain Momentum | DelveInsight

06-26-2025 08:19 PM CET | Health & Medicine

Press release from: DelveInsight

Diabetic Neuropathic Pain

Diabetic Neuropathic Pain

Diabetic neuropathic pain (DNP), a common and debilitating complication of diabetes, results from long-standing nerve damage due to chronic hyperglycemia. Characterized by burning sensations, tingling, numbness, and sharp pain, DNP severely affects patients' quality of life and functional ability. Despite several treatment options-mainly focused on symptomatic relief-there remains a considerable unmet need for safer, more effective, and disease-modifying therapies that can offer sustained benefits without central nervous system side effects or risk of addiction.

As of 2025, the diabetic neuropathic pain pipeline is witnessing a wave of novel therapeutics, with over 12 drug candidates under various stages of clinical and preclinical development. These include non-opioid analgesics, sodium channel blockers (NaV1.7 and NaV1.8 inhibitors), TRP channel modulators, SIRT1 activators, and neuroprotective agents aimed at slowing or reversing nerve damage. Companies such as Lexicon Pharmaceuticals, Biogen, JMackem, Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., Eli Lilly and Company are actively advancing novel mechanisms to target the root causes and improve long-term outcomes in DNP.

DelveInsight's report, "Diabetic Neuropathic Pain - Pipeline Insight, 2025", provides a detailed assessment of the evolving therapeutic landscape. The report offers in-depth insights into key assets in development, clinical trial progress, upcoming regulatory events, and strategic collaborations. It also highlights patient-centric innovations focused on reducing dosing frequency, minimizing systemic side effects, and enhancing treatment adherence.

With increasing R&D investment and growing awareness around diabetic complications, the pipeline is shifting from conventional symptom control toward multimodal and disease-modifying strategies. The emergence of precision medicine and biomarkers to identify patient subtypes further holds promise for tailored treatments. As these innovative candidates advance through clinical stages, the future of diabetic neuropathic pain management looks poised for a major transformation, offering renewed hope for millions suffering from this chronic condition.

Interested in learning more about the current treatment landscape and the key drivers shaping the diabetic neuropathic pain pipeline? Click here: https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Key Takeaways from the Diabetic Neuropathic Pain Pipeline Report
• DelveInsight's diabetic neuropathic pain pipeline analysis depicts a strong space with 10+ active players working to develop 12+ pipeline drugs for diabetic neuropathic pain treatment.
• The leading diabetic neuropathic pain companies include Lexicon Pharmaceuticals, Biogen, JMackem, Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., Eli Lilly and Company, Lateral Pharma Pty Ltd, Tris Pharma, Inc., and others are evaluating their lead assets to improve the diabetic neuropathic pain treatment landscape.
• Key diabetic neuropathic pain pipeline therapies in various stages of development include LX9211, Cemdomespib, AJH-2947, YJ001, LY3857210, LAT8881, GRT6005, and others.
• In January 2025, the FDA approved JOURNAVX, a first-in-class non-opioid analgesic targeting sodium channels, for moderate-to-severe acute pain. Vertex has received Breakthrough Therapy designation and is investigating suzetrigine for DPNP
• In December 2024, Sangamo Therapeutics announced FDA clearance of the investigational new drug (IND) application for its ST-503 program. This epigenetic therapy aims to address idiopathic small fiber neuropathy (iSFN), a chronic neuropathic pain condition that significantly impacts patients' quality of life.
• In November 2024, Sangamo Therapeutics, Inc. announced that the FDA has cleared the IND application for ST-503, an investigational epigenetic regulator aimed at treating intractable pain associated with idiopathic small fiber neuropathy (iSFN), a chronic neuropathic pain condition.

Request a sample and discover the recent breakthroughs happening in the diabetic neuropathic pain pipeline landscape at https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Neuropathic Pain Overview
Diabetic neuropathic pain is a prevalent and distressing complication of diabetes mellitus, marked by chronic pain resulting from damage to peripheral nerves. Symptoms commonly begin in the feet and gradually extend to the hands and other areas, often presenting as tingling, burning sensations, sharp or shooting pain, numbness, and increased sensitivity to touch. This discomfort tends to worsen at night, frequently disrupting sleep and significantly impairing patients' overall quality of life.

The development of diabetic neuropathic pain is driven by multiple interconnected factors. Prolonged hyperglycemia leads to nerve injury through mechanisms such as oxidative stress, inflammation, and metabolic disturbances. Compromised blood flow due to diabetic vascular complications further aggravates nerve damage. Genetic susceptibility, along with lifestyle factors like smoking and alcohol use, can also influence disease onset and severity. Diagnosis typically involves a comprehensive clinical evaluation, including a detailed patient history, neurological examination, and diagnostic tools such as nerve conduction studies and electromyography, supported by blood tests to monitor glucose control and exclude alternative neuropathies.

Find out more about diabetic neuropathic pain medication at https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Neuropathic Pain Treatment Analysis: Drug Profile
Cemdomespib: Biogen
Cemdomespib is an investigational oral small molecule and a selective C-terminal modulator of Hsp90. It is believed to exert its therapeutic effects by binding to the C-terminus of the Hsp90 protein, thereby enhancing the transcription of cytoprotective and molecular chaperone genes such as Hsp70. The upregulation of Hsp70, driven by Hsp90 modulation, is thought to provide neuroprotective benefits and alleviate diabetic nerve pain. Currently, Cemdomespib is in Phase II clinical development for the treatment of diabetic neuropathic pain.

LX9211: Lexicon Pharmaceuticals
LX9211 is an orally administered small molecule that targets adapter-associated kinase 1 (AAK1), a protein identified through Lexicon's target discovery program in collaboration with Bristol-Myers Squibb. Studies in AAK1-deficient mice have shown increased resistance to neuropathic pain, supporting the compound's therapeutic potential. LX9211 has demonstrated CNS penetration and efficacy in preclinical neuropathic pain models without engaging opioid pathways. The FDA has granted Fast Track designation to LX9211 for diabetic peripheral neuropathic pain. The drug is currently in Phase II trials for this indication.

Learn more about the novel and emerging diabetic neuropathic pain pipeline therapies at https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Diabetic Neuropathic Pain Therapeutics Assessment
By Product Type
• Mono
• Combination
• Mono/Combination.

By Stage
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

By Route of Administration
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical

By Molecule Type
• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Scope of the Diabetic Neuropathic Pain Pipeline Report
• Coverage: Global
• Key Diabetic Neuropathic Pain Companies: Lexicon Pharmaceuticals, Biogen, JMackem, Zhejiang Hanmai Pharmaceutical Technology Co., Ltd., Eli Lilly and Company, Lateral Pharma Pty Ltd, Tris Pharma, Inc., and others.
• Key Diabetic Neuropathic Pain Pipeline Therapies: LX9211, Cemdomespib, AJH-2947, YJ001, LY3857210, LAT8881, GRT6005, and others.

Dive deep into rich insights for drugs used for diabetic neuropathic pain treatment, visit: https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=jpr

Table of Contents
1. Introduction
2. Executive Summary
3. Diabetic Neuropathic Pain Pipeline: Overview
4. Analytical Perspective In-depth Commercial Assessment
5. Diabetic Neuropathic Pain Pipeline Therapeutics
6. Diabetic Neuropathic Pain Pipeline: Late-Stage Products (Phase III)
7. Diabetic Neuropathic Pain Pipeline: Mid-Stage Products (Phase II)
8. Diabetic Neuropathic Pain Pipeline: Early Stage Products (Phase I)
9. Therapeutic Assessment
10. Inactive Products
11. Company-University Collaborations (Licensing/Partnering) Analysis
12. Key Companies
13. Key Products
14. Unmet Needs
15. Market Drivers and Barriers
16. Future Perspectives and Conclusion
17. Analyst Views
18. Appendix

Contact Us:
Jatin Vimal
jvimal@delveinsight.com
+14699457679
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform, PharmDelve.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Diabetic Neuropathic Pain - Pipeline Insight, 2025: Innovation in Non-Opioid Therapies and Disease-Modifying Approaches Gain Momentum | DelveInsight here

News-ID: 4084004 • Views:

More Releases from DelveInsight

Hypovolemia Pipeline Insight 2025: Next-Gen Volume Expanders, Oxygen Therapeutics, and Field-Deployable Blood Products Revolutionizing Acute Care | DelveInsight
Hypovolemia Pipeline Insight 2025: Next-Gen Volume Expanders, Oxygen Therapeutic …
DelveInsight's "Hypovolemia - Pipeline Insight, 2025" provides a comprehensive overview of the therapeutic innovations aimed at managing this life-threatening condition characterized by rapid loss of circulating blood volume. Often triggered by trauma, surgery, gastrointestinal bleeding, or obstetric emergencies, hypovolemia remains a critical care challenge due to limited availability of blood products, logistical hurdles in emergency settings, and complications associated with excessive crystalloid use. The 2025 pipeline emphasizes the development of next-generation
Abdominal Aortic Aneurysm (AAA) Repair Devices Market to Register a CAGR of 5.70% by 2032, Driven by Rising Prevalence of Aneurysms, Technological Advancements, and Increasing Adoption of Minimally Invasive Procedures | DelveInsight
Abdominal Aortic Aneurysm (AAA) Repair Devices Market to Register a CAGR of 5.70 …
The global abdominal aortic aneurysm (AAA) repair devices market is poised for steady growth through 2032, supported by the rising prevalence of aneurysms among the aging population, lifestyle-related risk factors such as smoking and hypertension, and improved diagnostic detection rates. The increasing adoption of minimally invasive endovascular aneurysm repair (EVAR) devices over traditional open surgery is enhancing procedural safety, reducing hospital stays, and improving patient outcomes. Moreover, advancements in stent graft
Adult-Onset Still Disease Pipeline Insight 2025: IL-1/IL-6 Blockade, JAK Inhibitors, and Novel Immunomodulators Redefining Treatment Strategies | DelveInsight
Adult-Onset Still Disease Pipeline Insight 2025: IL-1/IL-6 Blockade, JAK Inhibit …
DelveInsight's "Adult-Onset Still Disease - Pipeline Insight, 2025" provides a detailed overview of the evolving therapeutic landscape for this rare systemic autoinflammatory disorder. Traditionally reliant on corticosteroids and conventional DMARDs, Adult-Onset Still Disease (AOSD) has long posed clinical challenges due to its relapsing course, systemic inflammation, and risk of complications such as macrophage activation syndrome. The 2025 pipeline highlights the growing dominance of targeted biologics, particularly IL-1 and IL-6 inhibitors, which
Laparoscopy Devices Market to Witness Robust Growth by 2032, Driven by Rising Minimally Invasive Surgeries and Technological Advancements | DelveInsight
Laparoscopy Devices Market to Witness Robust Growth by 2032, Driven by Rising Mi …
The laparoscopy devices market is expected to grow steadily through 2032, driven by the increasing adoption of minimally invasive surgical procedures across gastrointestinal, gynecological, and urological specialties. Advances in high-definition imaging, robotic-assisted systems, and energy-based surgical tools are enhancing precision, reducing recovery times, and improving patient outcomes. Additionally, the rising prevalence of chronic diseases, growing geriatric population, and increasing awareness of minimally invasive surgery benefits are expected to further propel

All 5 Releases


More Releases for Diabetic

Diabetic Socks Market Dynamics Shaped by Rising Diabetic Population - Persistenc …
The diabetic socks market is gaining significant traction worldwide, driven by the rising prevalence of diabetes and related complications such as diabetic neuropathy and foot ulcers. Designed specifically to cater to the needs of diabetic patients, these socks play a crucial role in foot protection by preventing blistering, reducing moisture accumulation, and providing cushioning to minimize the risk of ulcers. This article delves deeply into the diabetic socks market, exploring
Leading Element Driving Change in the Diabetic Footwear Market in 2025: Rising D …
Which drivers are expected to have the greatest impact on the over the diabetic footwear market's growth? The surge in people with diabetes will spur the expansion of the diabetic footwear market in the future. Diabetes, characterised by high blood sugar levels, is a long-term health issue. Diabetic footwear can prevent severe foot-related issues caused by diabetes and offer several advantages such as enhanced blood flow, ample space for the toes,
Diabetic Food Market
Future Market Insights (FMI) delivers key insights on the global diabetic food market in its latest report titled “Diabetic Food Market: Global Industry Analysis and Opportunity Assessment, 2014 – 2020”. The global diabetic food market is expected to amplify at a CAGR of 5.9% during the forecast period in terms of value due to various factors, regarding which FMI offers fundamental insights in detail in this report. On the basis of
Diabetic Food Market
Diabetes refers to a metabolic disease which leads to high blood sugar levels. The main cause behind diabetes is the insufficient insulin or no response in the body cells where the insulin is produced. Diabetic foods are dietary products rich in carbohydrates and sugar content. They help in controlling rising blood glucose. Diabetic food is low in calorie sweeteners and diet beverages. These products are consumed by diabetic patients and
Demand for Diabetic Socks Due to Rising Prevalence of Diabetic Neuropathy Expect …
According to the latest market report published by Persistence Market Research titled ‘Diabetic Socks Market: Global Industry Analysis 2012-2016 and Forecast 2017-2025,’ the global diabetic socks market is expected to expand at a CAGR of approximately 4.8% during the forecast period 2017-2025. To know key findings Request Sample Report @: https://www.persistencemarketresearch.com/samples/19282 Global Diabetic Socks Market: Factors Impacting the Market The primary factors driving the growth of the global diabetic socks market are increasing
Diabetic Food Market -
In recent times, diabetes has emerged as one of the most challenging health conditions across the world. According to the WHO, a total of 415 million cases of diabetes were reported globally in 2015. The count is rising at an alarming rate and is expected to reach 642 million in the next 25 years. Till now no medication has been found that can completely cure diabetes. It can only be